PlainPill

Hexarelin

Based on 4 first-hand reports and 0 meta-analyses & systematic reviews in the medical literature. Ranked #1525 of 1,974 overall.

7
User score
Not enough data
0% positive0% mixed0% negative100% unclear

Of reports that state an outcome, 0% are positive.

Clinical research
BModerate research base
0
meta-analyses
26
RCTs
291
papers
High-risk compound. Peptides are not approved as supplements, carry serious and sometimes irreversible risks, are banned in competitive sport and may be restricted where you live. Nothing here is a recommendation to use it.

What Hexarelin does, according to users

Of the people who reported each effect, the share who said it got better.

No specific effects reported yet.
betterno changeworse

What the research says

Systematic reviews and meta-analyses from PubMed, with their published conclusions.

BModerate research base

At least one meta-analysis, or 5+ randomized controlled trials. The grade measures how much human research exists — read the conclusions below for what it found.

No meta-analyses or systematic reviews published yet — 26 randomized trials found.

Dosage people report

As stated by users — not a recommendation. Follow the label or your doctor.

100 mcgas reported

Reported side effects

How often each side effect came up across all reports.

No side effects reported so far.

What users say

Verbatim quotes, shortened only — each links to the original discussion.

“I've taken the CJC NO DAC before with hexarelin and it seems to work well, although no blood work was done to check.”
Source discussion ↗
“Hexarelin is just as strong as GHRP-2 but affects Prolactin, and Cortisol at much higher levels, Hexarelin has been shown to desensitize no matter the dose”
Source discussion ↗
“such as GHRP-2, GHRP-6, ipamorelin, or hexarelin”
Source discussion ↗
Top discussions (3)

More peptides

User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 2, 2026. How we rate